AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03943771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety, renal anatomy and surgery questionnaires
Description: The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file.
Study NCT01472796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (cholecalciferol)
Description: Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
Study NCT01472796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tekturna(Aliskiren) plus placebo
Description: Aliskiren 300 mg per day supplemented with placebo
Study NCT01584999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: RBCs have been transfused in septic patient admitted in ICU
Study NCT00806728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
Study NCT02357121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Laser Ablation
Description: Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
Study NCT03781505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol +caudal ropivacaine
Description: Paracetamol + Ropivacaine
Study NCT03781505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caudal ropivacaine
Study NCT02140749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sc-FOS 2g/day
Description: Chewing tablets containing Short-chain fructooligosaccharides 2g/day
Study NCT02140749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sc-FOS 4g/day
Description: Chewing tablets containing short-chain Fructooligosaccharides 4g/day
Study NCT02140749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sc-FOS 8g/day
Description: Chewing tablets containing short-chain Fructooligosaccharides 8g/day
Study NCT02140749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Chewing tablets without short-chain Fructooligosaccharides
Study NCT02338050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox
Study NCT00632619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based behavior therapy
Description: Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
Study NCT00632619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stimulant medication therapy
Description: All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
Study NCT00632619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant medication therapy
Description: All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
Study NCT00632619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based psychosocial treatment
Description: Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
Study NCT04543695 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemoradiotherapy
Description: Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d
Study NCT04543695 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Radiotherapy:~50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d
Study NCT03640494 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
Study NCT00599248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C
Description: TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
Study NCT00599248 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (DMEM)
Study NCT04179318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Geneswell BCT
Description: Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
Study NCT01051362 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: PLD and Carboplatin
Description: Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
Study NCT01648530 — intervention group
Intervention type: OTHER
Intervention: No Treatment
Description: No Treatment
Study NCT05866965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF
Description: centrifuge patient's blood to collect 1 block of yellowish condensed fibrin, which is platelet-rich fibrin
Study NCT05866965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard third molar surgical removal
Description: standard third molar surgery following surgical protocol of Department of Oral Surgery, University of Medicine and Pharmacy
Study NCT04563936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01005 3.6 mg
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Study NCT04563936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOLADEX® 3.6 mg
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
Study NCT04206917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi Pulse Therapy
Description: The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
Study NCT02262455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STM 434
Description: STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
Study NCT00873626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
Description: Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
Study NCT02262455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
Study NCT03523936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic product
Description: Prebiotic product used during the course of antibiotic treatment
Study NCT03523936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03845192 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ORI measurement by Radical 97
Description: ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®.
Study NCT04257539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Reduce Sedentary Time
Description: Chronic low back pain participants in the intervention group will be provided with a wrist-worn activity device that vibrates after prolonged sedentariness and meet with a health coach trained in motivational interviewing to discuss individual sedentary levels and provide education surrounding sitting habits and strategies for new habit development. Participants will meet with the health coach initially and at 4 weeks during the 8 week intervention period.
Study NCT02223988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subglottic secretion removal
Study NCT04627792 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IUSECAMH Parent Intervention (Waitlist)
Description: We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
Study NCT01092858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undeconate (Nebido, BAY86-5037)
Description: Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
Study NCT01092858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
Study NCT02737774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
Study NCT02737774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
Study NCT02257281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Therapeutic Ultrasound
Description: For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
Study NCT02257281 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-active Therapeutic Ultrasound
Description: For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
Study NCT01223378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: ophthalmic solution, various concentrations, once daily (QD) 28 days
Study NCT01223378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: 0.005% ophthalmic solution, QD 28 days
Study NCT04837144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical Rehabilitation with MAK exoskeleton
Description: The participants will assist to 9 physical rehabilitation sessions with the MAK exoskeleton. During these sessions, different movements and therapies will be conducted using the studied device.
Study NCT03208686 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Group
Description: A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology - a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
Study NCT01325402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18Fluor]AZD4694
Description: Low mass dose below 5ug. High mass dose around 40 and 50 ug.
Study NCT01325402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18Fluor]AZD4694
Description: Low mass dose below 5ug. High mass dose around 20 ug.
Study NCT01325402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18Fluor]AZD4694
Description: Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
Study NCT02492867 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Response-driven Adaptive Radiation Therapy
Study NCT02492867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
Study NCT02492867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV
Study NCT02492867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Study NCT02492867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V/Q SPECT
Study NCT02492867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 mg/kg during consolidation. Given IV
Study NCT03757312 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
Study NCT03583996 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HepQuant SHUNT Liver Diagnostic Test
Description: One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
Study NCT03031171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening patient navigation
Description: The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
Study NCT03031171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Navigated
Description: Randomly matched sample of non-navigated clinic patients
Study NCT04087122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal warming device (Attune Medical, Chicago, IL
Description: Prospective, single center pilot stud
Study NCT00838448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise performed on a treadmill for 20-30 minutes
Study NCT02127632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube
Description: ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
Study NCT02127632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Supreme
Description: Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson \& Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7
Study NCT02000375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
Study NCT00793338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 20mg three times a day for 3 months.
Study NCT00006012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00006012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00006012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00006012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00006012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00006012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00006012 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00594061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation
Description: Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
Study NCT00886431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: embryo vitrification
Description: Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
Study NCT01772641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction + Varenicline
Description: Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
Study NCT01772641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction + Placebo Drug
Description: Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
Study NCT01772641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Advice + Varenicline
Description: Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
Study NCT01772641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic Advice + Placebo Drug
Description: Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
Study NCT03149250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aggregometry, Monitoring of plasmatic hemostasis
Description: Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
Study NCT03561181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
Study NCT03561181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
Study NCT01067404 — intervention group
Intervention type: BIOLOGICAL
Intervention: Trivalent inactivated influenza vaccine
Description: 0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
Study NCT01364428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted.